{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:27:51Z","timestamp":1750480071001},"reference-count":64,"publisher":"Elsevier BV","issue":"1-5","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1016\/s0960-0760(01)00159-5","type":"journal-article","created":{"date-parts":[[2002,10,15]],"date-time":"2002-10-15T13:27:27Z","timestamp":1034688447000},"page":"133-141","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy"],"prefix":"10.1016","volume":"79","author":[{"given":"Joseph","family":"Ragaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0960-0760(01)00159-5_BIB1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB3","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/S0140-6736(00)02277-7","article-title":"UK, USA breast cancer deaths down 25% in year 2000 at ages 20\u201369 years","volume":"355","author":"Peto","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB4","first-page":"1","article-title":"An overview of the breast cancer screening controversy. National Institute of Health Consensus Conference on Breast Cancer Screeining","volume":"8","author":"Kopans","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM199710023371401","article-title":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy Danish Breast Cancer Cooperative Group 82b Trial","volume":"337","author":"Overgaard","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199710023371402","article-title":"Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer","volume":"337","author":"Ragaz","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB7","first-page":"1022","author":"Henderson","year":"1996","journal-title":"Breast Cancer"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breats cancer: report of the National Surgical Adjuvant Breats and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB9","doi-asserted-by":"crossref","unstructured":"P.E. Goss, E.P. Winer, I.F. Tannock, L.H. Schwartz, North American Vorozole Study Group, Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients, J. Clin. Oncol. 17 (1999) 52\u201363.","DOI":"10.1200\/JCO.1999.17.1.52"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB10","unstructured":"A.U. Buzdar, W. Jonat, A. Howell et al., Arimidex Study Group, Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials, Cancer, 83 (1998) 1142\u20131152; published erratum appears in Cancer 85 (1999) 1010."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB12","first-page":"156a","article-title":"Letrozole, a new potent selective aromatase inhibitor superior to aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antiestrogens","volume":"16","author":"Marty","year":"1997","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB13","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB14","first-page":"27","article-title":"Femara (Letrozole) showed significant improvement in efficay over tamoxifen as first-line treatment in postmenopausal women with advanced breast cancer","volume":"58","author":"Smith","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB15","unstructured":"E. Simpson, M. Dowsett, W. Miller et al., Aromatase and its inhibitors\u2014the Port Douglas Aromatase 2000 Conference, Proceedings of the Aromatase 2000 Conference, Port Douglas, 2000."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/scientificamerican1098-60","article-title":"Designer estrogens","volume":"279","author":"Jordan","year":"1998","journal-title":"Sci. Am."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0039-128X(89)90076-7","article-title":"Novel steroidal pure antiestrogens","volume":"54","author":"Bowler","year":"1989","journal-title":"Steroids"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","article-title":"Response to a specific antiestrogen (ICI 182,780) in tgamoxifen-resistant breast cancer","volume":"345","author":"Howell","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","article-title":"Comparison of the effects of a pure antiestrogen with those of Tamoxifen in a model of human breast cancer","volume":"87","author":"Osborne","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB20","first-page":"547","article-title":"Combination of hormones for metastatic carcinoma of the breast: Aminoglutethimide plus Tamoxifen in combination versus Aminoglutethimide alone versus Tamoxifen alone","volume":"8","author":"Ragaz","year":"1981","journal-title":"Rev. Endocr. Relat. Cancer"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB21","first-page":"98a","article-title":"Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial","volume":"17","author":"Slamon","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB22","first-page":"97a","article-title":"Efficay and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breats cancer","volume":"17","author":"Cobleigh","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/90.18.1320","article-title":"Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?","volume":"90","author":"Clark","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB24","first-page":"97a","article-title":"The 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficay","volume":"17","author":"Bianco","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB25","first-page":"97a","article-title":"Initial report of the SWOG biological correlation study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen alone","volume":"90","author":"Ravdin","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB26","first-page":"3430","article-title":"Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma","volume":"42","author":"Smith","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB27","first-page":"3409","article-title":"Tamoxifen and aminoglutethimide in advanced breast cancer","volume":"42","author":"Corkey","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1986.4.6.958","article-title":"Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB29","first-page":"45","article-title":"A randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide and hydrocortisone","volume":"7","author":"Rose","year":"1986","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0140-6736(84)91872-5","article-title":"Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone and danazol, used in combination or sequentially","volume":"1","author":"Powles","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB31","first-page":"145","article-title":"Medical adrenalectomy with aminoglutethimide\u2014effect on response, and pituitary hormones","volume":"23","author":"Ragaz","year":"1981","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB32","first-page":"282","article-title":"Therapy of metastatic breast cancer with aminoglutethimide and tamoxifen\u2014role of systemic estrogens and pituitary hormones","volume":"2","author":"Ragaz","year":"1982","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB33","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jc.80.10.2918","article-title":"Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells","volume":"80","author":"Masamura","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1210\/en.141.1.396","article-title":"Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo","volume":"141","author":"Shim","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB35","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/83.20.1477","article-title":"Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxitamoxifen","volume":"83","author":"Osborne","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB36","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB37","first-page":"5183","article-title":"Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic nude mouse after long-term antiestrogen administration","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB38","first-page":"687","article-title":"Estrogen receptor variant in clinical breast cancer","volume":"3","author":"McGuire","year":"1991","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0960-0760(96)00078-7","article-title":"An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor","volume":"58","author":"Billimoria","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0959-8049(97)00100-7","article-title":"Oestrogen receptor mutants and variants in breast cancer","volume":"33","author":"Dowsett","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0883-2897(87)90014-6","article-title":"Mammary steroidogenesis: therapeutic implications","volume":"14","author":"Miller","year":"1987","journal-title":"Int. J. Radiat. Appl. Instrum. B"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00682738","article-title":"Regulation of aromatase expression in human tissues","volume":"30","author":"Bulun","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1023\/A:1008292329569","article-title":"Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study","volume":"8","author":"Boccardo","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB44","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.1998.16.6.2018","article-title":"Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes","volume":"16","author":"Ragaz","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB45","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifen","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S0960-0760(01)00159-5_BIB47","unstructured":"S.R. Cummings, S. Eckert, K.A. Krueger et al., The effect of Raloxifen on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifen Evaluation (see comments), JAMA 281 (1999) 2189\u20132197; published erratum appears in JAMA 282 (1999) 2124."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB48","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB49","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of Raloxifen on bone mineal density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/er.20.3.253","article-title":"Tamoxifen, Raloxifen, and the prevention of breast cancer","volume":"20","author":"Jordan","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB51","first-page":"2a","article-title":"Two year findings from the multiple outcomes of Raloxifen evaluation (MORE) trial","volume":"17","author":"Cummings","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB52","unstructured":"J. Robertson, R. Blamey, A. Howell, Duration of response to ICI 182,780 appears signifcantly longer than Megace in Tamoxifen-resistant breast cancer, Breast Cancer Res. Treat. (1995)."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB53","unstructured":"C. Osborne, Faslodex Intergroup Trials I (Faslodex vs Anastrozole) and II (Faslodex vs Tamoxifen). K. Osborne, personal communications, 2000."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB54","unstructured":"J. Ragaz, Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy, Proceedings of Aromatase 2000 and 3rd Generation, Port Douglas, 2000, p. 23."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB55","unstructured":"N. MacPherson, J. Ragaz, A. Brodie, Intermittent and sequential use of multiple hormonal agents in experimental therapy of breast cancer: determination of optimum use in a preparation of a clinical trial, personal communications, 2000."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB56","unstructured":"R. Noble, Intermittent hormonal therapy delays autonomouth tumor growth in experimental Noble rat tumors, personal communications, 1983."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB57","unstructured":"N. Bruchovsky, Intermittent use of anti-adrogen therapy in prostate cancer: delayed resistance, personal communications, 1987."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB58","first-page":"556","article-title":"Endocrine treatment of breast cancer","volume":"5","author":"Ravdin","year":"1994","journal-title":"Curr. Ther. Endocrinol. Metab."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB59","first-page":"29","volume":"58","author":"Ellis","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/gye.13.s6.1.8","article-title":"Selective enzyme modulators","volume":"6","author":"Pasqualini","year":"1999","journal-title":"Gynecol. Endodrinol."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB61","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB62","first-page":"1604","article-title":"Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy","volume":"60","author":"Rubin","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3835(00)00435-3","article-title":"Effects of pinostrobin on estrogen metabolism and estrogen receptor transactivation","volume":"156","author":"Le Bail","year":"2000","journal-title":"Cancer Lett."},{"key":"10.1016\/S0960-0760(01)00159-5_BIB64","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0024-3205(00)00435-5","article-title":"Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells","volume":"66","author":"Le Bail","year":"2000","journal-title":"Life Sci."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076001001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076001001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T20:56:54Z","timestamp":1556830614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076001001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":64,"journal-issue":{"issue":"1-5","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0960076001001595"],"URL":"https:\/\/doi.org\/10.1016\/s0960-0760(01)00159-5","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}